Cargando…
Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued
Fabry disease is an X-linked disease due to a deficiency of the lysosomal enzyme alpha-galactosidase A. Clinical symptoms in classically affected males include acroparesthesia, anhydrosis and angiokeratoma, which may present during childhood followed by cardiac, cerebral and renal complications. Eve...
Autor principal: | Politei, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274950/ https://www.ncbi.nlm.nih.gov/pubmed/32561366 http://dx.doi.org/10.1016/j.ymgme.2020.06.002 |
Ejemplares similares
-
Should AMOC observations continue: how and why?
por: Frajka-Williams, E., et al.
Publicado: (2023) -
Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
por: Cabrera, Gustavo, et al.
Publicado: (2017) -
Fabry Disease Patient-Reported Outcome (FD-PRO) demonstrates robust measurement properties for assessing symptom severity in Fabry disease
por: Hamed, Alaa, et al.
Publicado: (2021) -
Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment
por: Politei, Juan M., et al.
Publicado: (2016) -
Collateral impact of COVID-19: why should children continue to suffer?
por: Nagakumar, Prasad, et al.
Publicado: (2021)